WWWieland Alexander Worthoff

Wieland Alexander Worthoff

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wieland Alexander Worthoff has a total of 78 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    QRAGE—Simultaneous multiparametric quantitative MRI of water content, T1, T2*, and magnetic susceptibility at ultrahigh field strength

    by Markus Zimmermann, Zaheer Abbas, Yannic Sommer, Alexander Lewin, Shukti Ramkiran, Jörg Felder, Wieland A. Worthoff, Ana‐Maria Oros‐Peusquens, Seong Dae Yun, N. Jon Shah

    Purpose: To introduce quantitative rapid gradient‐echo (QRAGE), a novel approach for the simultaneous mapping of multiple quantitative MRI parameters, including water content, T1, T2*, and magnetic susceptibility at ultrahigh field strength.Methods: QRAGE leverages a newly developed multi‐echo MPnRAGE sequence, facilitating the acquisition of 171 distinct contrast images across a range of TI and TE points. To maintain a short acquisition time, we introduce MIRAGE2, a novel model‐based reconstruction method that exploits prior knowledge of temporal signal evolution, represented as damped complex exponentials. MIRAGE2 minimizes local Block‐Hankel and Casorati matrices. Parameter maps are derived from the reconstructed contrast images through postprocessing steps. We validate QRAGE through extensive simulations, phantom studies, and in vivo experiments, demonstrating its capability for high‐precision imaging.Results: In vivo brain measurements show the promising performance of QRAGE, with test–retest SDs and deviations from reference methods of < 0.8% for water content, < 17 ms for T1, and < 0.7 ms for T2*. QRAGE achieves whole‐brain coverage at a 1‐mm isotropic resolution in just 7 min and 15 s, comparable to the acquisition time of an MP2RAGE scan. In addition, QRAGE generates a contrast image akin to the UNI image produced by MP2RAGE.Conclusion: QRAGE is a new, successful approach for simultaneously mapping multiple MR parameters at ultrahigh field.


  • Open Access

    A Modified Quadrature Birdcage Coil Incorporated With a Curved Feature for In Ovo MR Imaging

    by Chang-Hoon Choi, Maximilian Bruch, Suk-Min Hong, Sandra Krause, Carina Stegmayr, Stefan Schwan, Wieland A. Worthoff, Jörg Felder, N. Jon Shah

    Goal: This study presents a novel MRI coil design approach explicitly tailored for chick embryo measurements, with the primary objective of improving sensitivity and coverage. Methods: The limitations posed by conventional birdcage coils were addressed by introducing a curvature feature into a standard coil. The performance of the modified coil was assessed using EM simulations and experimental evaluations, which were subsequently validated using a 7 T MRI scanner. A comparative analysis was conducted against a standard quadrature low-pass birdcage coil to evaluate key factors. Results: The proposed coil demonstrated improved SNR and uniformity, particularly in the proximity of the end-rings. These results were consistent with the findings obtained from the simulations. Conclusions: The use of our innovative birdcage coil design holds promise and offers practical potential for in ovo studies.


  • Open Access

    Hybrid PET/MRI in Cerebral Glioma: Current Status and Perspectives

    by Karl-Josef Langen, Norbert Galldiks, Jörg Mauler, Martin Kocher, Christian Peter Filß, Gabriele Stoffels, Cláudia Régio Brambilla, Carina Stegmayr, Antje Willuweit, Wieland Alexander Worthoff, et al.

    Advanced MRI methods and PET using radiolabelled amino acids provide valuable information, in addition to conventional MR imaging, for brain tumour diagnostics. These methods are particularly helpful in challenging situations such as the differentiation of malignant processes from benign lesions, the identification of non-enhancing glioma subregions, the differentiation of tumour progression from treatment-related changes, and the early assessment of responses to anticancer therapy. The debate over which of the methods is preferable in which situation is ongoing, and has been addressed in numerous studies. Currently, most radiology and nuclear medicine departments perform these examinations independently of each other, leading to multiple examinations for the patient. The advent of hybrid PET/MRI allowed a convergence of the methods, but to date simultaneous imaging has reached little relevance in clinical neuro-oncology. This is partly due to the limited availability of hybrid PET/MRI scanners, but is also due to the fact that PET is a second-line examination in brain tumours. PET is only required in equivocal situations, and the spatial co-registration of PET examinations of the brain to previous MRI is possible without disadvantage. A key factor for the benefit of PET/MRI in neuro-oncology is a multimodal approach that provides decisive improvements in the diagnostics of brain tumours compared with a single modality. This review focuses on studies investigating the diagnostic value of combined amino acid PET and ‘advanced’ MRI in patients with cerebral gliomas. Available studies suggest that the combination of amino acid PET and advanced MRI improves grading and the histomolecular characterisation of newly diagnosed tumours. Few data are available concerning the delineation of tumour extent. A clear additive diagnostic value of amino acid PET and advanced MRI can be achieved regarding the differentiation of tumour recurrence from treatment-related changes. Here, the PET-guided evaluation of advanced MR methods seems to be helpful. In summary, there is growing evidence that a multimodal approach can achieve decisive improvements in the diagnostics of cerebral gliomas, for which hybrid PET/MRI offers optimal conditions.


  • Open Access

    Hybrid PET/MRI in Neuro-oncology: Current Status and Perspectives

    by Karl-Josef Langen, Norbert Galldiks, Jörg Mauler, Martin Kocher, Christian P. Filss, Gabriele Stoffels, Claudia Regio-Brambilla, Carina Stegmayr, Antje Willuweit, Wieland A. Worthoff, et al.

    Advanced MRI methods and PET using radiolabeled amino acids provide valuable information in addition to conventional MR imaging for brain tumor diagnostics. These methods are particularly helpful in challenging situations such as the differentiation of malignant processes from benign lesions, the identification of non-enhancing glioma subregions, the differentiation of tumor progression from treatment-related changes, and the early assessment of response to anticancer therapy. The debate over which of the methods is preferable in which situation is ongoing and has been addressed in numerous studies. Currently, most radiology and nuclear medicine departments perform these examinations independently of each other leading to multiple examinations for the patient. The advent of hybrid PET/MRI allowed a convergence of the methods but to date simultaneous imaging has reached little relevance in clinical neuro-oncology. This is partly due to the limited availability of hybrid PET/MRI scanners, but is also due to the fact that PET is a second-line examination in brain tumors. PET is only required in equivocal situations, and spatial co-registration of PET examinations of the brain to previous MRI is possible without disadvantage. A key factor for the benefit of PET/MRI in neuro-oncology is a multimodal approach that provides decisive improvements in the diagnostics of brain tumors compared with a single modality. This systematic review focuses on studies that were able to demonstrate the additive value of amino acid PET and ‘advanced’ MRI in the diagnosis of brain tumors. Available studies suggest that the combination of amino acid PET and advanced MRI improves grading and the histomolecular characterization of newly diagnosed tumors. However, data concerning the delineation of tumor extent and biopsy guidance are of limited value. A clear additive diagnostic value of amino acid PET and advanced MRI can be achieved regarding the differentiation of tumor recurrence from treatment-related changes. Here, PET-guided evaluation of advanced MR methods seems to be helpful. In summary, there is growing evidence that a multimodal approach can achieve decisive improvements in the diagnostics of brain tumors, for which hybrid PET/MRI offers optimal conditions.


  • Open Access

    Two Decades of Brain Tumour Imaging with O-(2-[18F]fluoroethyl)-L-tyrosine PET: The Forschungszentrum Jülich Experience

    by Alexander Heinzel, Daniela Dedic, Norbert Galldiks, Philipp Lohmann, Gabriele Stoffels, Christian P. Filss, Martin Kocher, Filippo Migliorini, Kim N. H. Dillen, Stefanie Geisler, et al.

    O-(2-[18F]fluoroethyl)-L-tyrosine (FET) is a widely used amino acid tracer for positron emission tomography (PET) imaging of brain tumours. This retrospective study and survey aimed to analyse our extensive database regarding the development of FET PET investigations, indications, and the referring physicians’ rating concerning the role of FET PET in the clinical decision-making process. Between 2006 and 2019, we performed 6534 FET PET scans on 3928 different patients against a backdrop of growing demand for FET PET. In 2019, indications for the use of FET PET were as follows: suspected recurrent glioma (46%), unclear brain lesions (20%), treatment monitoring (19%), and suspected recurrent brain metastasis (13%). The referring physicians were neurosurgeons (60%), neurologists (19%), radiation oncologists (11%), general oncologists (3%), and other physicians (7%). Most patients travelled 50 to 75 km, but 9% travelled more than 200 km. The role of FET PET in decision-making in clinical practice was evaluated by a questionnaire consisting of 30 questions, which was filled out by 23 referring physicians with long experience in FET PET. Fifty to seventy per cent rated FET PET as being important for different aspects of the assessment of newly diagnosed gliomas, including differential diagnosis, delineation of tumour extent for biopsy guidance, and treatment planning such as surgery or radiotherapy, 95% for the diagnosis of recurrent glioma, and 68% for the diagnosis of recurrent brain metastases. Approximately 50% of the referring physicians rated FET PET as necessary for treatment monitoring in patients with glioma or brain metastases. All referring physicians stated that the availability of FET PET is essential and that it should be approved for routine use. Although the present analysis is limited by the fact that only physicians who frequently referred patients for FET PET participated in the survey, the results confirm the high relevance of FET PET in the clinical diagnosis of brain tumours and support the need for its approval for routine use.


  • Open Access

    Compressed Sensing in Sodium Magnetic Resonance Imaging: Techniques, Applications, and Future Prospects

    by Qingping Chen, N. Jon Shah, Wieland A. Worthoff

    Sodium (23Na) yields the second strongest nuclear magnetic resonance (NMR) signal in biological tissues and plays a vital role in cell physiology. Sodium magnetic resonance imaging (MRI) can provide insights into cell integrity and tissue viability relative to pathologies without significant anatomical alternations, and thus it is considered to be a potential surrogate biomarker that provides complementary information for standard hydrogen (1H) MRI in a noninvasive and quantitative manner. However, sodium MRI suffers from a relatively low signal‐to‐noise ratio and long acquisition times due to its relatively low NMR sensitivity. Compressed sensing‐based (CS‐based) methods have been shown to accelerate sodium imaging and/or improve sodium image quality significantly. In this manuscript, the basic concepts of CS and how CS might be applied to improve sodium MRI are described, and the historical milestones of CS‐based sodium MRI are briefly presented. Representative advanced techniques and evaluation methods are discussed in detail, followed by an expose of clinical applications in multiple anatomical regions and diseases as well as thoughts and suggestions on potential future research prospects of CS in sodium MRI.Evidence Level: 5Technical Efficacy: Stage 1


  • Open Access

    An in vivo multimodal feasibility study in a rat brain tumour model using flexible multinuclear MR and PET systems

    by Chang-Hoon Choi, Carina Stegmayr, Aliaksandra Shymanskaya, Wieland A. Worthoff, Nuno A. da Silva, Jörg Felder, Karl-Josef Langen, N. Jon Shah

    Background: In addition to the structural information afforded by 1H MRI, the use of X-nuclei, such as sodium-23 (23Na) or phosphorus-31 (31P), offers important complementary information concerning physiological and biochemical parameters. By then combining this technique with PET, which provides valuable insight into a wide range of metabolic and molecular processes by using of a variety of radioactive tracers, the scope of medical imaging and diagnostics can be significantly increased. While the use of multimodal imaging is undoubtedly advantageous, identifying the optimal combination of these parameters to diagnose a specific dysfunction is very important and is advanced by the use of sophisticated imaging techniques in specific animal models. Methods: In this pilot study, rats with intracerebral 9L gliosarcomas were used to explore a combination of sequential multinuclear MRI using a sophisticated switchable coil set in a small animal 9.4 T MRI scanner and, subsequently, a small animal PET with the tumour tracer O-(2-[18F]-fluoroethyl)-L-tyrosine ([18F]FET). This made it possible for in vivo multinuclear MR-PET experiments to be conducted without compromising the performance of either multinuclear MR or PET. Results: High-quality in vivo images and spectra including high-resolution 1H imaging, 23Na-weighted imaging, detection of 31P metabolites and [18F]FET uptake were obtained, allowing the characterisation of tumour tissues in comparison to a healthy brain. It has been reported in the literature that these parameters are useful in the identification of the genetic profile of gliomas, particularly concerning the mutation of the isocitrate hydrogenase gene, which is highly relevant for treatment strategy. Conclusions: The combination of multinuclear MR and PET in, for example, brain tumour models with specific genetic mutations will enable the physiological background of signal alterations to be explored and the identification of the optimal combination of imaging parameters for the non-invasive characterisation of the molecular profile of tumours.


  • Open Access

    Relaxometry and quantification in sodium MRI of cerebral gliomas: A FET‐PET and MRI small‐scale study

    by Wieland A. Worthoff, Aliaksandra Shymanskaya, Johannes Lindemeyer, Karl‐Josef Langen, N. Jon Shah

    Sodium MRI is a promising method for assessing the metabolic properties of brain tumours. In a recent study, a strong relationship between semi‐quantitative abnormalities in sodium MRI and the mutational status of the isocitrate dehydrogenase enzyme (IDH) with untreated cerebral gliomas was observed. Here, sodium relaxometry in brain tumour tissue was investigated in relation to molecular markers in order to reveal quantitative sodium tissue parameters and the differences between healthy tissue and brain tumour. The previous semi‐quantitative approach is extended by use of suitable relaxometry methods accompanied by numerical simulation to achieve detailed quantitative analysis of intra‐ and extracellular sodium concentration using an enhanced SISTINA sequence at 4 T. Using optimised techniques, biexponential sodium relaxation times in tumour (T*2f, T*2s) and in healthy contralateral brain tissue (T*2f,CL, T*2s,CL) were estimated in 10 patients, along with intracellular sodium molar fractions (χ, χCL), volume fractions (η, ηCL) and concentrations (ρin, ρin,CL). The total sodium tissue concentrations (ρT, ρT,CL) were also estimated. The ratios T*2f/T*2f,CL (P = .05), η/ηCL (P = .02) and χ/χCL (P = .02) were significantly lower in IDH mutated than in IDH wildtype gliomas (n = 4 and n = 5 patients, respectively). The Wilcoxon rank‐sum test was used to compare sodium MRI parameters in patients with and without IDH mutation. Thus, quantitative analysis of relaxation rates, intra‐ and extracellular sodium concentrations, intracellular molar and volume fractions based on enhanced SISTINA confirmed a relationship between abnormalities in sodium parameters and the IDH mutational status in cerebral gliomas, hence catering for the potential to provide further insights into the status of the disease.